Effect of recombinant human endostatin on radiosensitivity in patients with non-small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 4, 2012, Pages 1272-1277

  Jiang, Xiao Dong ^a   Dai, Peng ^a   Wu, Jin ^a   Song, Da An ^a   Yu, Jin Ming ^b  

^a Lianyungang First People's Hospital   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Hypoxia; Non small cell lung cancer; Radiotherapy; Recombinant human endostatin

Indexed keywords

BLOOD FLOW; COMPLETE RESPONSE; ENDOSTATINS; HYPOXIA; LOCAL CONTROL; MEDIAN SURVIVAL TIME; METASTATIC LYMPH NODES; NON SMALL CELL LUNG CANCER; NORMAL TISSUE; OVERALL SURVIVAL RATES; PARTIAL RESPONSE; THERAPEUTIC EFFECTS; TOTAL DOSE;

DISEASES; PATHOLOGY; TISSUE;

RADIOTHERAPY;

HYPOXIA INDUCIBLE FACTOR 1ALPHA; RECOMBINANT ENDOSTATIN; TECHNETIUM 99M;

ADULT; AGED; AGRANULOCYTOSIS; ANEMIA; ANGINA PECTORIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGITIS; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION ESOPHAGITIS; RADIATION PNEUMONIA; RADIOSENSITIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR REGRESSION; TUMOR VOLUME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; ENDOSTATINS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION TOLERANCE; RADIOTHERAPY, INTENSITY-MODULATED; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 84862645716     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.09.050     Document Type: Article

References (18)

1. Govindan R. Management of patients with non-small cell lung cancer and poor performance status. Curr Treat Options Oncol 2003;4:55-59.
2. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215.
3. Seo Y, Yan T, Schupp JE, et al. Differential radiosensitization in DNA mismatch repair proficient and deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-20-deoxyribose. Clin Cancer Res 2004;10:7520-7528.
4. Toma-Daşu I, Daşu A, Karlsson M. The relationship between temporal variation of hypoxia, polarographic measurements and predictions of tumour response to radiation. Phys Med Biol 2004;49:4463-4475.
5. Ling CH, Ji C, Chen YB, et al. Combined effects of endostatin gene transfer and ionizing radiation on lung adenocarcinoma model of A549 cells. Zhonghua Jie He He Hu Xi Za Zhi 2004;27:683-686.
6. Luo X, Andres ML, Timiryasova TM, et al. Radiation-enhanced endostatin gene expression and effects of combination treatment. Technol Cancer Res Treat 2005;4:193-202.
7. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
8. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-563.
9. Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol 2010;136:1201-1211.
10. Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxiainducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-4696.
11. WHO handbook for reporting results of cancer treatment. Offset Publication No. 48. Geneva: World Health Organization; 1979.
12. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
13. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996;2:167-168.
14. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
15. O'Reilly MS, Boehm T, Shing Y. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
16. Wang J, Sun Y, Liu Y, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 2005;8:283-290.
17. Jiang XD, Dai P, Wu J, et al. Inhibitory effects of radiotherapy combined with weekly recombinant human endostatin on the human pulmonary adenocarcinoma A549 xenografts in nude mice. Lung Cancer 2011;72:165-171.
18. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.